ReviewInternational journal of nanomedicine2020
Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy.
Review in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 109 citations in OpenAlex.
- Evaluation of Histidine-Octamer-Modified Hyaluronic Acid as a Cytosolic Drug Delivery Material via CD44-Mediated Cellular Uptake and Endosomal Escape.Pharmaceutics · 2026Article
- Surface decoration of solid lipid nanoparticles with cyclic RGD peptides for precision therapy in high-risk neuroblastoma.Drug delivery and translational research · 2026Article
- Membrane Curvature and Cancer: Mechanisms, Implications, and Therapeutic Perspectives.Cancers · 2026Review
- Smart Nanoformulations for Oncology: A Review on Overcoming Biological Barriers with Active Targeting, Stimuli-Responsive, and Controlled Release for Effective Drug Delivery.Pharmaceutics · 2026Review
- Harnessing nanomedicine to target NF-κB signalling in cancer: at the intersection of inflammatory signalling, metabolic reprogramming, and therapeutic innovation.Cell communication and signaling : CCS · 2026Review
- Physicochemical design of nanobiomaterials in oncology: structure-to-function principles for sequential transport and delivery.Frontiers in oncology · 2026Review
- Liposomal Nanoparticulate Drug Delivery Systems: Strategies to Destabilize Biological Membranes at the Target Tissue.International journal of nanomedicine · 2026Review
- Recent Advances in Organelle-Targeted Drug Delivery: Precision Medicine at the Subcellular Level.Current drug targets · 2026Review
- CD44 Receptor-Mediated Delivery of ROS/pH Dual-Sensitive Nanoparticles Based on Poly(Ethylene Glycol)-International journal of nanomedicine · 2026Article
- Coconut oil/lauric acid-based nanodrug formulation: a multifunctional platform for enhancing cancer therapy and mitigating toxicity.Frontiers in cell and developmental biology · 2026Review
- Stability and Selectivity of Indocyanine Green Towards Photodynamic Therapy of CRL-2314 Breast Cancer Cells with Minimal Toxicity to HTB-125 Cells.Molecules (Basel, Switzerland) · 2025Article
- Natural Polysaccharide-Based Nanoparticles Enhance Intracellular Delivery and Cytotoxicity ofInternational journal of molecular sciences · 2025Article
- Organelle-oriented nanomedicines in tumor therapy: Targeting, escaping, or collaborating?Bioactive materials · 2025Review
- Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside.Molecular cancer · 2025Review
- Developments in nanotechnology approaches for the treatment of solid tumors.Experimental hematology & oncology · 2025Review
- Establishment of a chemoresistant laryngeal cancer cell model to study chemoresistance and chemosensitization responses via transcriptomic analysis and a tumor-on-a-chip platform.Bioengineering & translational medicine · 2025Article
- Radiation-induced ferroptosis via liposomal delivery of 7-Dehydrocholesterol.Journal of nanobiotechnology · 2025Article
- Herbal Nanoformulations for Diabetes: Mechanisms, Formulations, and Clinical Impact.Current diabetes reviews · 2025Review
- Advancing Nanomedicine Through Electron Microscopy: Insights Into Nanoparticle Cellular Interactions and Biomedical Applications.International journal of nanomedicine · 2025Review
- Recent advances in targeted drug delivery systems for multiple myeloma.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomedicines (NMs) have played an increasing role in cancer therapy as carriers to efficiently deliver therapeutics into tumor cells. For this application, the uptake of NMs by tumor cells is usually a prerequisite to deliver the cargo to intracellular locations, which mainly relies on endocytosis. NMs can enter cells through a variety of endocytosis pathways. Different endocytosis pathways exhibit different intracellular trafficking routes and diverse subcellular localizations. Therefore, a comprehensive understanding of endocytosis mechanisms is necessary for increasing cellular entry efficiency and to trace the fate of NMs after internalization. This review focuses on endocytosis pathways of NMs in tumor cells, mainly including clathrin- and caveolae-mediated endocytosis pathways, involving effector molecules, expression difference of those molecules between normal and tumor cells, as well as the intracellular trafficking route of corresponding endocytosis vesicles. Then, the latest strategies for NMs to actively employ endocytosis are described, including improving tumor cellular uptake of NMs by receptor-mediated endocytosis, transporter-mediated endocytosis and enabling drug activity by changing intracellular routes. Finally, active targeting strategies towards intracellular organelles are also mentioned. This review will be helpful not only in explicating endocytosis and the trafficking process of NMs and elucidating anti-tumor mechanisms inside the cell but also in rendering new ideas for the design of highly efficacious and cancer-targeted NMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.